MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $13.60 (145.93% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016Robert W. BairdInitiated CoverageNeutral$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016Brean CapitalReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/20/2016MizuhoReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015GuggenheimInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.30)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q4($0.23)($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.12)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.32)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114($0.30)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateHeadline
06/28/16 04:58 PMCovering the Bases on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK): Where is the Stock Going? - Press Telegraph
06/27/16 03:09 PMHere's Why Merrimack Pharmaceuticals' Stock Has Been Getting Crushed in 2016 -
06/27/16 09:25 AMMerrimack Pharmaceuticals, Inc. (MACK) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 09:25 AMMerrimack Pharmaceuticals Incorporated (NASDAQ:MACK) Sellers Increased By 5.26% Their Shorts - Press Telegraph
06/26/16 04:23 PMLexicon Pharmaceuticals, Inc. versus Merrimack Pharmaceuticals, Inc. Head to Head Compare - CML News
06/25/16 04:42 PMMost Recent Analysts Ratings Report: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) , Minerva Neurosciences, Inc ... - Street Updates
06/25/16 08:52 AMMerrimack Pharmaceuticals Inc Has Another Very Weak Trading Session - Engelwood Daily
06/25/16 08:52 AMStrong Sell Calls Recommendations For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) At 0 - Investor Newswire
06/23/16 07:47 AMMerrimack Pharma (MACK) to Present Phase 3 NAPOLI-1 Data Analysis at ESMO
06/23/16 07:47 AMAn analysis of the Phase 3 NAPOLI-1 safety data across patient subgroups will also be presented
06/22/16 04:57 PMWorth Watching Active Movers: Lennar Corporation (NYSE:LEN), Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - NYSE Journal (press release)
06/22/16 09:47 AMMerrimack Pharmaceuticals (NASDAQ:MACK) Analyst Rating Consensus - TheFounders Daily
06/21/16 04:44 PMMerrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
06/21/16 09:31 AMWatch List: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Xplore Technologies Corp. (NASDAQ:XPLR), Allegion ... - KC Register
06/20/16 06:28 AMThis Weeks Broker Views For Merrimack Pharmaceuticals, Inc. (MACK) - Fiscal Standard
06/19/16 09:07 AMStrong Buy Calls Count For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) At 3 - Investor Newswire
06/17/16 04:55 PMGlobal Ewing Sarcoma Pipeline Review 2016 - Research and Markets
06/17/16 04:55 PMGlobal Ewing Sarcoma Pipeline Review 2016 - Research and Markets
06/17/16 07:52 AMTrading Overview of Two Stocks: Hill-Rom Holdings Inc (NYSE:HRC) , Merrimack Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
06/16/16 05:13 PMElizabeth Arden : Cosmetics maker Revlon to buy Elizabeth Arden in $870 million deal
06/16/16 03:56 PMMERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/16/16 09:21 AMTwo Buzzers within Traders Radar: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) , Merrimack Pharmaceuticals, Inc ... - Street Updates
06/15/16 05:02 PMPrice Review of Stocks: PDL BioPharma, Inc. (NASDAQ:PDLI) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates
06/14/16 04:50 PMAnalyst Price Target Update on Merrimack Pharmaceuticals (NASDAQ:MACK) - TheFounders Daily
06/13/16 07:57 AMWatch List: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), U.S. Bancorp (NYSE:USB), Urban Outfitters Inc ... - KC Register
06/13/16 07:57 AMEarnings Report of the Stocks: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), The Bank of Nova Scotia (NYSE:BNS) - Beacon Chronicle
06/11/16 07:53 AMNoteworthy Analysts Suggestions: Thermo Fisher Scientific Inc (NYSE:TMO) , Merrimack Pharmaceuticals, Inc ... - Street Updates
06/11/16 07:53 AMMerrimack Pharmaceuticals, Inc. Stock Momentum Hits Extreme Weakness - CML News
06/11/16 07:53 AMMerrimack Pharmaceuticals Inc. (MACK) Drops 5.2% on June 09 - Equities.com
06/10/16 07:58 AMTraders Targeted Movers: Perrigo Company (NYSE:PRGO) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates
06/09/16 05:17 PMMovers inside Traders Limelight: Cigna Corporation (NYSE:CI) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates
06/08/16 07:55 AMMERRIMACK PHARMACEUTICALS INC. (NASDAQ:MACK) Financial Condition Compared to S&P 500 - CML News
06/07/16 05:15 PMMerrimack Pharmaceuticals (MACK) Is Weak On High Volume Today - TheStreet.com
06/07/16 05:15 PMAnalyst Recommendations: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Neurocrine Biosciences Inc. (NASDAQ ... - Beacon Chronicle
06/07/16 07:42 AMStocks within Traders Screening: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) , Neurocrine Biosciences, Inc ... - Street Updates
06/06/16 04:58 PMBRIEF-Merrimack Pharmaceuticals posts results from refractory solid tumor study - Reuters
06/06/16 04:58 PMAnalyst Ratings on: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), WP GLIMCHER Inc. (NYSE:WPG) - Beacon Chronicle
06/06/16 08:46 AMMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Insiders Look Optimistic About Prospects - iStreetWire
06/06/16 08:46 AMCompany Update (NASDAQ:MACK): Merrimack Pharmaceuticals Inc Announces Final Analysis of First-in-Human ... - Smarter Analyst
06/06/16 07:13 AMBRIEF-Merrimack Pharmaceuticals posts results from refractory solid tumor study - * Announced results from final analysis of phase 1 study of mm-151 in patients with refractory solid tumors
06/06/16 06:31 AM7:31 am Merrimack Pharma announces final analysis of phase 1 study of MM-151, showing 'positive' clinical activity in multiple solid tumor types; results presented at the ASCO annual meeting -
06/06/16 06:30 AMFinal Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer - [PR Newswire] - CAMBRIDGE, Mass., June 6, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal ...
06/04/16 07:49 AMBaird Initiates Coverage on Merrimack Pharmaceuticals Inc to Neutral - Trade Calls
06/03/16 06:55 AMThese 7 Stocks Under $10 Are About to Break Out -
06/02/16 05:23 PMNoteworthy Price Swings: PerkinElmer, Inc. (NYSE:PKI) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Street Updates - iStreetWireNoteworthy Price Swings: PerkinElmer, Inc. (NYSE:PKI) , Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)Street UpdatesOn 6/1/2016, PerkinElmer, Inc. (NYSE:PKI) highlighted upward shift of +0.13% or +0.07 points to $54.82. The company traded a volume of 1.17 million shares over average volume of 669.36 thousand shares. Trailing twelve month period, the firm has ...How Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) trades after earning announcements?ZergwatchMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) 1-Year High At $13.00Equities FocusMerrimack Pharmaceuticals, Inc. (MACK) Analyst ReviewRisers & FallersEquities.com -Street Report -Stock Tick Tockall 12 news articles »
06/02/16 07:56 AMStock Review and Earnings Check on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - HNN - Stock Review and Earnings Check on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Merrimack Pharmaceuticals, Inc.and more »
06/01/16 07:55 AMHC Stocks in Front Line: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Merrimack Pharmaceuticals Inc (NASDAQ ... - share market updates (press release) - HC Stocks in Front Line: Pernix Therapeutics Holdings Inc (NASDAQ:PTX), Merrimack Pharmaceuticals Inc (NASDAQ ...share market updates (press release)Shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) closed at $0.440 with 2.70 million shares getting traded. Post opening the session at $0.44, the shares hit an intraday low of $0.43 and an intraday high of $0.46 and the price vacillated in this ...
06/01/16 07:55 AMNotable Analysts Recommendation to Monitor: AbbVie Inc. (NYSE:ABBV) , Merrimack Pharmaceuticals, Inc. (NASDAQ ... - Street Updates - iStreetWireNotable Analysts Recommendation to Monitor: AbbVie Inc. (NYSE:ABBV) , Merrimack Pharmaceuticals, Inc. (NASDAQ ...Street UpdatesOn 5/31/2016, AbbVie Inc. (NYSE:ABBV) ended trading session higher at $62.93 with +0.35%. The company traded a volume of 7.15 million shares as comparison to average volume of 7.6 million shares. During the 52 –week period, the stock's price traded ...Merrimack Pharmaceuticals, Inc. (MACK) Analyst ReviewRisers & FallersMerrimack Pharmaceuticals Inc. (MACK) Jumps 5.71% on May 31Equities.comAnalysts and Technical Insights on Merrimack Pharmaceuticals Inc (NASDAQ:MACK)Street ReportiStreetWireall 5 news articles »
05/31/16 05:16 PMShare Rating Focus on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - HNN - Share Rating Focus on Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.5 on shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research.and more »
05/31/16 05:16 PMStocks Growth Estimates Watch: Legg Mason Inc (NYSE:LM), Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - News Oracle - Stocks Growth Estimates Watch: Legg Mason Inc (NYSE:LM), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)News OracleThe stock gained 1.13% and closed its last session at $34.13. The Company has the market capitalization of 3.64 Billion. The 52-Week Range ranges between $24.93 and $55.13. The stock traded with the Volume of 1.16 Million in the last trading day ...and more »
About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MACK
  • CUSIP: 59032810
Key Metrics:
  • Previous Close: $5.53
  • 50 Day Moving Average: $6.46
  • 200 Day Moving Average: $6.93
  • P/E Ratio: N/A
  • P/E Growth: -1.46
  • Market Cap: $706.32M
  • Current Quarter EPS Consensus Estimate: $-0.75 EPS
Additional Links:
Merrimack Pharmaceuticals (NASDAQ:MACK) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha